EdenDx is the first and only non-invasive liquid-based cytology test in the U.S. for early endometrial cancer detection—one of the four most common cancers among women. Using DNA methylation analysis from a routine cervical brush to assess cancer risk with clarity and confidence, it helps guide biopsy decisions and reduce unnecessary procedures, without disrupting routine care.
How EdenDx Works
Designed for simplicity and built for impact, EdenDx transforms a familiar cervical brush into a powerful tool for early detection. With no new equipment or workflow changes, providers can collect a sample in minutes and receive a clear, binary result that helps guide next steps and reduce unnecessary procedures.
Collect with ThinPrep® cervical brush
Use the same collection process as a Pap smear—no uterine access or new tools requiredSend to Gnosis
Sample is processed using real-time PCR to detect gene methylationReceive binary results
Providers receive a clear report indicating positive or negative risk
Why EdenDx Matters
EdenDx, short for “Early Detection of Endometrial Neoplasia,” is closing gaps in women’s cancer detection.
- 69,120 new cases of endometrial cancer are expected in the U.S. in 2025
-
30% of endometrial biopsies fail due to insufficient tissue, causing delays in diagnosis and treatment
-
Transvaginal ultrasound (TVUS) can be inconclusive in premenopausal patients, limiting its effectiveness in early evaluation
-
Women with high body mass index (BMI), polycystic ovary syndrome (PCOS), or limited access to care are less likely to receive timely testing, contributing to later-stage diagnoses
Molecular insight
Molecular insight
EdenDx analyzes hypermethylation of CDO1 and CELF4 to detect endometrial cancer risk early. This targeted molecular approach delivers high clinical accuracy from a simple cervical brush, bringing earlier insight to more patients, with less burden.
High-risk focus
EdenDx is designed for women at elevated risk of endometrial cancer, including those with abnormal bleeding, inconclusive imaging, or underlying conditions like Lynch syndrome or breast cancer treated with Tamoxifen. It also supports evaluation in patients with high BMI, PCOS, or hormonal imbalances, delivering early insight when and where it’s most needed.
Faster answers
With a turnaround time of 3-7 days and no need for histological processing, EdenDx accelerates the diagnostic timeline. Clinical validation shows 97.8% specificity and 85.3% sensitivity, helping providers act sooner, even when tissue sampling or imaging falls short.
Designed for Everyday Care
EdenDx complements imaging and clinical judgment by providing early molecular insight when traditional evaluations leave questions unanswered. Whether used after inconclusive ultrasound or during the workup of abnormal bleeding, EdenDx equips providers with actionable results that help determine when biopsy is truly necessary. It’s not a replacement for diagnosis—it’s a smarter way to prioritize care.
Over 75 million women in the U.S. are at risk for endometrial cancer. Worldwide, more than 200 million women could benefit from earlier, non-invasive evaluation, especially those with high BMI, PCOS, or limited access to specialty care. EdenDx was developed to help meet that need without disrupting what already works.
Our Services
Our Laboratory
Our cutting-edge laboratory is a beacon of scientific innovation. Within its walls, a dedicated team of leading scientists and licensed laboratory technicians harness the most advanced diagnostic testing available.
Visit Us
Visit our laboratory, specimen collection locations, or patient service centers. For our most up-to-date list of locations, please click through to learn more.
Billing
We’re here to help! If you have any inquiries or require assistance to ensure a smooth billing experience for your patients, please feel free to reach out to us at support@gnosisdx.com.